Envoy Medical Surpasses Three-Month Visit Milestone for All 56 Patients in Pivotal Clinical TrialArticle content White Bear Lake, Minnesota–(Newsfile Corp. – July 21, 2026) – Envoy Medical® Inc. (NASDAQ: COCH) (“Envoy Medical” or the “Company”), a hearing health company pioneering fully implanted hearing solutions, today announced that it has surpassed the three-month milestone for all 56 patients enrolled in the Company’s pivotal clinical trial evaluating the investigational fully implanted Acclaim® cochlear implant. To be added to the Envoy Medical email distribution list, please email Envoy@kcsa.com with COCH in the subject line. Article content About the Fully Implanted Acclaim® Cochlear Implant We believe the fully implanted Acclaim Cochlear Implant (“Acclaim CI”) is a first-of-its-kind hearing device. Forward-Looking Statements This press release includes “forward-looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995. Envoy Medical does not guarantee that the events described will happen as described (or that they will happen at all).